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Background: Smooth muscle cell (SMC) migration and proliferation are early and crucial events in the pathogenesis of
intimal hyperplasia, the primary cause of restenosis after vascular intervention. We tested the hypothesis that protein
kinase C- (PKC), a ubiquitously expressed intracellular protein kinase, regulates vascular SMC proliferation and
migration.
Methods: Exogenous PKC was expressed in cultured SMCs via stable transfection or adenovirus-mediated gene transfer.
Conversely, endogenous PKCwas inhibited by means of targeted gene deletion (gene knock-out). Cell proliferation and
migration were determined by 3H-thymidine incorporation and 24-well transwell assay, respectively.
Results: We isolated and examined three A10 SMC lines in which PKC was stably transfected. Compared with cells that
were transfected with an empty vector, cells transfected with PKC exhibited reduced ability to proliferate. Moreover,
PKC transfection inhibited SMC migration toward platelet-derived growth factor-BB. Similar inhibitory effects on
proliferation and migration were also observed when PKC was introduced into primary aortic SMCs via an adenoviral
vector. Interestingly, SMCs isolated from PKC knockout mice also displayed decreased chemotaxis and proliferation
compared with PKC/ littermates, suggesting a complex yet critical role for PKC. We studied the mitogen-activated
protein kinase extracellular signal-regulated kinases (ERK) 1/2 as a possible signaling pathway for PKC’s inhibitory
effect. PKC overexpression diminished ERK1/2 activity. Molecular restoration of ERK activation reversed the
inhibitory effect of PKC on SMC proliferation and migration.
Conclusions:We demonstrate that although normal migration and proliferation is lessened in SMCs deficient in PKC, its
prolonged activation also diminishes those behaviors. This suggests a dual, critical role for PKC in SMC proliferation
and migration, and thus intimal hyperplasia and restenosis. ( J Vasc Surg 2007;45:160-8.)
Clinical Relevance: Restenotic or hyperplastic lesions are typified by dedifferentiated vascular smooth muscle cells
(VSMC) that demonstrate excessive proliferation and migration. We have previously demonstrated that protein kinase
C- (PKC) is a critical upstream factor leading to VSMC apoptosis. The present study shows that PKC, when
ectopically expressed in VSMCs, also inhibits proliferation and migration as well as extracellular signal-regulated
mitogen-activated protein kinase. Thus, gene transfer of PKC is a potential molecular therapeutic strategy to inhibit
intimal hyperplasia.The intima of a normal human artery is almost entirely
free of smooth muscle cells (SMCs). Subsequent to the
trauma and altered hemodynamics of vascular reconstruc-
tion, however, SMCs of the media are stimulated to mi-
grate into the subintimal space. The proliferation of these
cells within this layer contributes to the phenomenon of
neointimal hyperplasia, the major obstacle to the long-term
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160success of vascular interventions for the treatment of ath-
erosclerotic disease. The migration of SMCs into and their
proliferation within the subintima is thus central to the
pathogenesis of this costly, morbid, and unsolved dilemma.
Members of the protein kinase-C (PKC) family are
activated by diverse stimuli as mediators of multiple
processes such as cellular growth, differentiation, and
apoptosis. In previous studies, we identified several PKC
isotypes expressed by SMCs, including , I, II, , ε, ,
and .1 The novel PKC isoform PKC is the only one of
these that has been shown to be associated with the cy-
toskeleton,2 implying a possible role in migration.
PKC has been demonstrated to inhibit growth in
many cell types, including fibroblasts,3 capillary endothelial
cells,4 and airway SMCs.5 The evidence from these investi-
gations suggests that PKC does so by halting the cell cycle
at various points, depending on the cell type; however, the
detailed molecular mechanisms through which PKC influ-
ences cell cycle progression remain unclear. Similarly, little
is known about how PKC regulates SMC migration.
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mediators of nuclear and cytoplasmic responses to extracel-
lular stimuli. They phosphorylate cytoplasmic substrates
and activate specific genes by modulating a variety of tran-
scription factors. The MAPK family consists of three major
subfamilies with multiple members: the extracellular signal-
regulated kinases (ERK), c-Jun N-terminal kinases (JNK),
and p38 MAP-kinases (p38). Each MAPK is activated in
response to diverse extracellular stimuli by phosphorylation
within a conserved Thr-X-Tyr motif in its activation loop.
Ample in vitro studies using cultured vascular endothelial
and SMCs, as well as in vivo experiments with injured
arteries, link MAPK activation to cell proliferation, migra-
tion, and apoptosis.6-8 Specifically, the critical role of
ERK1/2 in vascular SMC proliferation and intimal hyper-
plasia has been well established.9,10
In this report, we examine the role of PKC in vascular
SMC behavior by testing a hypothesis that high PKC
activity inhibits both SMC proliferation and migration. We
also elucidate the role of MAPK ERK1/2 as a downstream
mediator after PKC activation. These studies provide an
explicit link between PKC and ERK1/2 in the process of
SMC migration and proliferation. These findings have po-
tential to improve approaches for the prevention and man-
agement of restenosis.
METHODS
General materials. Platelet-derived growth factor
(PDGF)-BB was obtained from R &D Systems (Minneap-
olis, Minn). Dimethyl sulfoxide (DMSO) and other chem-
icals, if not specified otherwise, were purchased from Sigma
Chemical Co (St. Louis, Mo). Dulbecco Modified Eagles
Medium (DMEM) and cell culture reagents were from
Gibco BRL Life Technologies (Gaithersburg, Md). Mouse
monoclonal anti-phospho-myelin basic protein was pur-
chased from Upstate Biotechnologies Inc (Lake Placid,
NY). Rabbit polyclonal antibody to ERK1/2 and phospho-
ERK1/2 were obtained from Cell Signal (Beverley, Mass).
Rabbit polyclonal anti-PKC was obtained from Santa
Cruz Biotechnology Inc (Santa Cruz, Calif).
Smooth muscle cell culture. Rat aortic A10 SMCs,
obtained from the American Tissue Culture Collection,
were grown as recommended in DMEM modified to con-
tain 4 mM L-glutamine, 4.5 g/L glucose, 1mM sodium
pyruvate, and 1.5 g/L sodium bicarbonate supplemented
with 10% fetal bovine serum (FBS) and antibiotics. The
generation of PKC target deletion was described else-
where.11 Both rat and mouse aortic SMCs were isolated
from the thoracic aorta based on a protocol described by
Clowes et al12 and maintained in DMEM containing 10%
FBS at 37°C with 5% carbon dioxide.
Immunoblotting. Protein extracts were resolved by
electrophoresis as described previously.13 Equal amounts
of protein extracts were separated by sodium dodecyl sul-
fate polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to a polyvinylidene diflouride membrane and
blotted with antibodies. Labeled proteins were visualizedwith an ECL system (Amersham Biosciences, Piscataway,
NJ).
Proliferation assay. Proliferation was assayed by eval-
uating DNA synthesis and counting cell numbers. In DNA
synthesis assay, cells were seeded onto 24-well plates at the
concentration of 10,000 cells/well in 10% FBS-DMEM
and allowed to attach overnight. SMCs were starved in
0.5% FBS-DMEM for 48 hours and then stimulated for 24
hours with agonists as indicated. During the final 4 hours of
the assay, 2 Ci of [methyl 3H]-thymidine was added to
each well and co-incubated. Protein was precipitated with
10% trichloroacetic acid, and radioactivity of incorporated
3H-thymidine was determined by using a liquid scintilla-
tion counter. For cell counting, cells were seeded onto 24
well plates at a density of 10,000 cells/well in 10% FBS-
DMEM (day 0) and medium was replaced every other day.1
Cell numbers were determined by hemacytometer on the
indicated days.
Chemotaxis assay. Chemotaxis was determined using
a 24-well transwell (Poretics Corp, Livermore, Calif) con-
taining polycarbonate 8-m-pore membrane filters. Cells
harvested by using 0.05% trypsin/ethylenediaminetet-
raacetic acid were seed in upper wells in 0.5% FBS media at
a density of 10,000 (A10) or 40,000 (rat and mouse aortic)
cells/well. PDGF-BB, diluted in 0.5% FBS media to
5 ng/mL, was applied into the lower wells. Cells were then
incubated in the carbon dioxide incubator at 37°C for
4 hours (A10) or 6 hours (rat and mouse aortic).
On completion of the assay, membranes were removed,
fixed in 70% ethanol at –20°C for 30 minutes, and stained
with hematoxylin at room temperature for 30minutes. The
upper side of the membrane was scraped using a cotton
swab to remove cells that had attached but not migrated,
and the membrane was then mounted onto a microscope
slide. Chemotaxis in each well was assessed by counting the
number of cells in five independent, high-power fields
(original magnification 200).
Construction of adenoviral vectors and infection.
A recombinant adenoviral vector was constructed to ex-
press PKC. Briefly, a DNA fragment containing the de-
sired sequence was generated by polymerase chain reaction
(PCR) using the human complimentary DNA (cDNA) as a
template. After DNA sequencing, the PCR product was
then cloned into an E1- and E3-deficient adenoviral vector
(pEasy). Adenoviruses were propagated in human embry-
onic kidney (HEK) 293 cells and purified by cesium chlo-
ride density gradient centrifugation. SMCs were infected
with adenoviruses as described previously.13
Mitogen-activated protein kinase assay. The ERK
activity was measured using a MAPK IP-kinase assay kit
(Upstate Biotechnology, Waltham, Mass). Cells were lysed
with buffer containing 1% Nonidet P-40. Lysates were
immunoprecipitated with an anti-ERK1/2 antibody im-
mobilized with agarose. After four rounds of vigorous
washing, the immunoprecipitated complexes were sub-
jected to a phosphorylation assay usingmyelin basic protein
as a substrate, which was analyzed by immunoblotting
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Statistical analysis. Values are expressed as mean 
standard error. The unpaired Student’s t test was used to
evaluate the statistical differences between the control and
treated groups. Values of P 	 .05 were considered signifi-
cant. All experiments were performed with n  3 and
repeated at least three times.
RESULTS
Protein kinase C-–overexpressing vascular smooth
muscle cells demonstrate decreased proliferation and
migration. To evaluate the role of PKC in SMC prolifer-
ation and migration, two processes critical to the patho-
physiology of intimal hyperplasia, we established PKC-
overexpressing SMC lines by stably transfecting A10 cells
with a full-length human PKC cDNA inserted into the
pTracerSV40 vector. The empty pTracerSV40 vector was
used as a control. Transfected cells were selected for their
resistance to the antibiotic Zeocin (Invitrogen, Carlsbad,
Calif) and the presence of pTracerSV40 vector sequences.
Using such approach, we isolated three clones (PKC 3, 4,
and 5) that were successfully transfected with
PKCpTracerSV40 and two clones (PT3 and 4) transfected
with the empty vector. The amount of PKC protein
expressed in these clones was evaluated by immunoblotting
with a PKC specific antibody. The level of PKC was
significantly increased in PKC-transfected cells (PKC 3,
4, and 5) compared with wild-type A10 or empty vector
PT3 and 4 cells (Fig 1, A). Expression of other PKC
isotypes was not affected by the PKC transfection (data
not shown).
Because of the important contribution of SMC prolifera-
tion to intimal hyperplasia,we evaluated the ability of PKC to
influence proliferation of A10 SMCs. All cells were seeded on
day 0 at the same density and were allowed to grow in a
medium containing 10% FBS to days 1, 3, 5, and 7. As shown
in Fig 1, A, the growth rate of PKC-overexpressing cells was
markedly reduced compared with that of wild-type or
empty vector. At day 7, the number of PKC cells was
	50% of the control cells.
To confirm the inhibitory effect of PKC on SMC
growth, we evaluated the effect of PKC on DNA synthesis
using a 3H-thymidine incorporation assay. Wild-type A10
cells, empty vector clones (PT3 and 4), and PKC clones
(PKC 3, 4, and 5) were made quiescent by incubation in
0.5% serum and then treated with PDGF-BB (5 ng/mL) or
control solvent for 24 hours. Compared with wild-type
A10 SMCs and empty vector controls, all cell lines overex-
pressing PKC demonstrated significantly reduced basal
and PDGF-stimulated DNA synthesis (Fig 1, B).
Because the migration of SMCs from the media to
the intima is also essential for neointima formation, we
continued by evaluating SMC migration in our PKC-
overexpressing cell lines. A modified Boyden chamber
assay was used to seed wild-type A10 cells, empty vector
clones (PT3 and 4), and PKC clones (PKC 3, 4, and 5)
into the upper well of a microchemotaxis chamber(10,000 cells/well), and migration through an 8-m
porous membrane was measured. PDGF-BB (5 ng/mL)
was added to the lower well as the chemotactic stimulus.
All cell lines overexpressing PKC demonstrated signifi-
cantly reduced basal and PDGF-stimulated chemotaxis
compared with empty vector controls (Fig 1, C ).
Because A10 SMCs are of embryonic origin and their
behavior has been found to resemble SMCs derived from
hyperplastic lesions rather than normal medial SMCs,14 we
determined that it was necessary to confirm the effects of
PKC on proliferation and migration in arterial SMCs
isolated from adult animals. To this end, we used the
adenovirus-mediated gene transfer technique to over
express PKC in SMCs isolated from the aorta of adult
rats (RASMCs). We constructed a recombinant adeno-
viral vector to express the wild-type PKC (AdPKC)
from a replication-deficient adenovirus as described in
the Methods section. To confirm the expression of
adenovirus-mediated expression of PKC, RASMCs
were infected with AdPKC or an empty viral vector
(AdNull) at a dosage of 30,000 particles/cell. Cell lysates
were resolved by SDS-PAGE and immunoblotted with
anti-PKC or anti--actin antibodies. As a result of trans-
gene expression, higher levels of PKC were found in
AdPKC-infected cells (Fig 2, A).
To assess cell proliferation, RASMCs were seeded at
low density after infection with AdNull or AdPKC and
allowed to grow in the presence of 10% serum. The number
of cells was counted at 1, 2, 5, and 7 days after seeding.
AdPKC significantly inhibited cell growth (Fig 2, A).
Similarly, basal and PDGF-stimulated DNA synthesis was
alsomarkedly suppressed by the ectopic expression of PKC
(Fig 2, B). Taken together, these data indicate that PKC
plays a similar inhibitory role in cell proliferation of adult
arterial SMCs.
Next, we examined the effect of adenoviral-mediated
overexpression of PKC on migration of RASMCs. Forty-
eight hours after viral infection, RASMCs were subjected to
the chemotaxis assay in which the number of cells that
migrated through a porous membrane toward PDGF-BB
(5 ng/mL) was measured. AdPKC significantly reduced
the number of migrated RASMCs (Fig 2, C). These data
further support PKC’s inhibitory effect on vascular SMC
migration.
Selective protein kinase C- gene deletion also de-
creases vascular smooth muscle cell proliferation and
migration. To further elucidate the effect of PKC on vas-
cular SMC migration and proliferation, we used PKC
“knock-out” SMCs11 as an experimental approach to inhibit
endogenous PKC activity. We first confirmed the absence of
PKC in SMCs harvested from PKC–/– mice by usingWest-
ern blot analysis (Fig 3, A). We next seeded SMCs, isolated
from PKC null and wild-type littermates, at low density and
allowed them to grow in the presence of 10% serum. The
number of cells was counted at 1, 2, 4, and 8 days after
seeding. PKC gene deletion significantly inhibited cell
growth (Fig 3, A). We then used a 3H-thymidine incorpora-
Fig 1. Protein kinase C- (PKC) overexpressing A10 smooth
muscle cell (SMC) lines demonstrate decreased proliferation
and chemotaxis. Data are expressed as mean  standard error.
A, A10, empty vector (PT3, PT4), or PKC (PKC 3, 4, and 5)
cells were seeded into 24-well plates at a density of 10,000
cells/well on day 0 and maintained in 10% fetal bovine serum.
Cells were counted on days 1, 3, 5, and 7 (n 
 3). *P 	 .05,
compared with control A10 SMC line. B, A10, empty vector, or
PKC cells were serum-starved for 48 hours and then stimulated
for 24 hours with or without 5 ng/mL platelet-derived growth
factor-BB (PDGF-BB). Incorporation of 3H-thymidine was
measured (n 
 3, #P 	 0.05, compared to A10 basal; *P 	
0.01, compared to A10 treated with PDGF-BB). C, A10, empty
vector, or PKC cells were made quiescent and then subjected
to the chemotaxis assay as described in Experimental Procedures
(n 
 3, #P 	 .01, compared with A10 basal; *P 	 0.01,
compared with A10 treated with PDGF-BB).Fig 2. Protein kinase C- (PKC) overexpression in adult rat aortic
smooth muscle cells (RASMCs), via adenoviral transfection, inhibits
proliferation and migration. Data are expressed as mean  standard
error.A,RASMCswere infectedwith AdNull or AdPKC. Cells were
lysed and analyzed by immunoblotting 48 hours after infection.
Additional infected cells were reseeded into 24-well plates at a density
of 10,000 cells/well on day 0 and maintained in 10% fetal bovine
serum. Cells were counted on days 1, 2, 5, or 7 (n 
 3, *P 	 0.01,
compared to corresponding AdNull-infected cells).B,After infection
with AdNull or AdPKC, RASMCswere serum-starved for 48 hours.
Basal and platelet-derived growth factor-BB (PDGF-BB)–induced
DNA synthesis was measured using the 3H-thymidine incorporation
(n 
 3, *P 	 0.01, compared to AdNull control or PDGF-BB). C,
RASMCs were infected with AdNull or AdPKC. Basal and
PDGF-BB (5 ng/mL) induced chemotaxis was evaluated 48 hours
after infection (n
 3, *P	 .05, compared with AdNull control).
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DNA synthesis. Vascular SMCs from both PKC/ and
PKC–/– mice were made quiescent by incubation in 0.5%
serum and then treated with PDGF-BB (5 ng/mL) for 24
hours. Compared with wild-type SMCs, PKC null SMCs
demonstrated both decreased basal and PDGF-stimulated
DNA synthesis (Fig 3, B).
Next, we examined the effect of PKC gene deletion on
the migration of mouse aortic SMCs as in previous experi-
ments. Without a chemotactic stimulus, both PKC null and
wild-type cells demonstrated low rates of chemotaxis. How-
ever, in response to PDGF-BB (5 ng/mL), PKC–/– SMCs
demonstrated significantly decreased chemotaxis (Fig 3, C).
Protein kinase C- overexpression inhibits extracel-
lular signal-regulated kinase 1/2 activity. To elucidate
the mechanism by which the ectopic expression of PKC
inhibits SMC proliferation and migration, we used our
stably transfected A10 SMCs and examined the MAPK
ERK1/2, previously demonstrated to be essential for both
SMC migration and proliferation.9,15 Control A10 SMCs
exhibited a detectable basal level of ERK1/2 activity as
measured by phosphorylation of its substrate myelin basic
protein. Stimulation with PDGF-BB (5 ng/mL for 15
minutes) greatly enhanced ERK1/2 activity, as anticipated
(Fig 4, A). Both basal and PDGF-stimulated ERK1/2 activity
was significantly diminished in PKC-overexpressing cell lines
cells, with compatible amounts of ERK1/2 found in all
clones (Fig 4, A), suggesting that PKC had no effect on
protein expression of ERK1/2 and the low activity was
due to a downregulation of MAPK activity in PKC cells.
We next tested whether manipulation of PKC in
RASMCs would affect ERK1/2 activation. Forty-eight
hours after adenoviral infection, cells were stimulated with
PDGF-BB (5 ng/mL for 15 minutes) and ERK1/2 was
immunoprecipitated from cell lysates. ERK1/2 activity in
the immunocomplex was again measured by its ability to
phosphorylate its substrate myelin basic protein. As in our
prior experiment, PDGF-BB markedly increased ERK1/2
activity (Fig 4, B). This PDGF-stimulated ERK1/2 activa-
tion was significantly diminished by AdPKC. These results
are consistent with our previous findings in stably trans-
fected A10 cells.
Fig 3. Protein kinase C- (PKC) selective gene deletion down-
regulates smooth muscle cell (SMC) proliferation and migration. A,
Mouse SMCswere isolated fromPKC–/– and PKC/ littermates.
SMCs frombothgroupswere lysed and analyzedby immunoblotting.
Additional cells were seeded into 24-well plates at a density of 10,000
cells/well on day 0 and maintained in 10% fetal bovine serum. Cells
were counted on days 1, 2, 4, and 8 (n
 3, *P	 .05, compared with
PKC/ control). B, PKC/ and PKC/ SMCs were serum-
starved for 48 hours and then stimulated for 24 hours with or without
platelet-derived growth factor-BB (PDGF-BB)(5 ng/mL). The in-
corporation of 3H-thymidine was measured (n 
 3, *P 	 0.01,
compared to PKC/ control or PDGF-BB). C, PKC–/– and
PKC/ SMCs were serum-starved for 48 hours. Chemotaxis with
and without PDGF-BB (5 ng/mL) was evaluated as described in
Experimental Procedures (n
 3, *P	 0.05, compared to PKC/PDGF-BB).
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phorylation of ERK1/2 as an additional assay of MAPK
activity. We found that compared with RASMCs infected
Fig 4. Protein kinase C- (PKC) overexpression inhibits extra-
cellular signal-regulated kinase 1/2 (ERK1/2) activity. A, A10,
PKC, or vector transfected cells were made quiescent by incuba-
tion in the low-serum media for 48 hours. Cells were stimulated
with platelet-derived growth factor-BB (PDGF-BB) (5 ng/mL for
15 minutes). Cell lysates were immunoprecipitated with an anti-
ERK1/2 antibody. The activity of ERK in the IP complex was
measured by its ability to phosphorylate myelin basic protein
(MBP). B, Adult rat aortic smooth muscle cells (RASMCs) were
infected with AdNull or AdPKC. After serum starvation for 48
hours and PDGF-BB treatment (5 ng/mL for 15 minutes) were
indicated, cell lysates were immunoprecipitated with an anti-
ERK1/2 antibody and ERK activity in the IP complex was mea-
sured by its ability to phosphorylate MBP. C, RASMCs were
infected with AdNull or AdPKC. After serum starvation and
PDGF-BB treatment (5 ng/mL for 15 minutes), cell lysates un-
derwent Western blot analysis with anti-ERK1/2 antibodies. D,
Mouse SMCs from PKC/ and PKC/ littermates under-
went low-serum incubation and stimulation with PDGF-BB
(5 ng/mL for 15 minutes). Cell lysates were immunoprecipitated
with an anti-ERK1/2 antibody and ERK activity in the IP complex
was measured by MBP phosphorylation.with the empty viral vector, those infected with AdPKCdemonstrated significantly decreased amounts of PDGF-
induced ERK1/2 phosphorylation (Fig 4, C). Finally, we
evaluated basal and PDGF-BB–stimulated ERK1/2 activ-
ity in PKC null SMCs. Compared with SMCs from their
wild-type littermates, PKC gene deletion led to decreased
PDGF-stimulated ERK1/2 activity (Fig 4, D). These re-
sults mirror the data acquired from our previous migration
and proliferation studies.
Overexpression of constitutively active MAPK/
ERK kinase (MEK) rescues protein kinase C-’s inhi-
bition of proliferation and migration. To provide fur-
ther evidence that ectopic expression of PKC influences
SMC behavior through its downregulation of ERK1/2, we
restored ERK1/2 activity in SMCs overexpressing PKC
by adenoviral transfection of a constitutively active MEK
mutant (AdMEK), an approach we have previously used to
selectively activate ERK1/2 in SMCs.13 A10 SMCs were
infected with equal quantities of AdNull, AdPKC, or
AdMEK (60,000 total viral particles/cell). After low serum
incubation, A10 cells, with or without PDGF-BB (5 ng/
mL), underwent measurement of 3H-thymidine incorpo-
ration. The A10 SMCs receiving AdNull alone demon-
strated low levels of DNA synthesis under basal conditions
but responded dramatically to PDGF stimulation (Fig 5,
A). The A10 cells receiving PKC in combination with
AdNull responded with a blunted response to the mitogen,
whereas PKC-overexpressing cells that were transfected
with AdMEK returned to normal levels of both basal and
PDGF-stimulated 3H-thymidine incorporation (Fig 5, A).
Next, we evaluated A10 SMC migration under similar
conditions. A10 cells were again infected with equal quan-
tities of AdNull, AdPKC, or AdMEK (60,000 total viral
particles/cell). After low serum incubation, A10 cells un-
derwent a transwell chemotaxis assay with and without
PDGF-BB stimulation. SMCs overexpressing PKC alone
demonstrated significantly reduced basal and PDGF-
stimulated chemotaxis (Fig 5, B), whereas A10 SMCs in-
fected with both AdPKC and AdMEK exhibited migra-
tion similar to those infected with empty vector controls
(Fig 5, B).
DISCUSSION
We used both genetic and molecular manipulation to
demonstrate that PKC is critical to proliferation and mi-
gration in vascular SMCs. PKC overexpression in both
A10 and rat aortic SMCs, accomplished by stable transfec-
tion and adenoviral gene transfer, respectively, resulted in a
suppression of proliferation and chemotaxis. We also pro-
vide evidence that PKC overexpression selectively sup-
presses activation of the ERK1/2 subclass of MAP kinases.
This suppression may underlie the effect of PKC overex-
pression on proliferation and migration.
The role of PKC in cell proliferation has been studied
in several cell types, including vascular SMCs. With the
exception of certain transformed and cancerous cells, PKC
was found to play a generally inhibitory role in prolifera-
tion.16 This ability of PKC to negatively or positively
regulate proliferation may depend on its phosphorylation.
JOURNAL OF VASCULAR SURGERY
January 2007166 Liu et alAs shown in NIH 3T3 cells, a PKC tyrosine mutant
(Tyr155 ¡ Phe) stimulates cell proliferation, whereas the
wild-type PKC inhibits it.17 The PKC molecule contains
19 tyrosine residues, and at least nine have been implicated
as sites of phosphorylation. It is not clear, however, how
PKC phosphorylation is related to its inhibition of vascular
SMC proliferation. Additional studies using site-specific
mutations are needed to clarify the effect of PKC phos-
phorylation on its regulation of SMC proliferation.
The observed reduction of about 40% in cell number
and DNA synthesis could also be influenced by changes in
cell apoptosis or necrosis. Indeed, we have previously found
Fig 5. Protein kinase C-’s (PKC) inhibition of migration and
proliferation can be overcome by restoring extracellular signal-
regulated kinase 1/2 (ERK1/2) activity. Data are expressed as
mean  standard error. A, After low-serum incubation for 48
hours, incorporation of 3H-thymidine was measured in A10
smooth muscle cells (SMCs) infected with equal quantities of
AdNull, AdPKC, or AdMEK (60,000 total viral particles/cell)
and stimulated for 24 hours with or without platelet-derived
growth factor-BB (PDGF-BB) (5 ng/mL) (n 
 3, P 	 0.05,
compared to AdNull PDGF-BB). B, AdNull, AdPKC, or Ad-
MEK infected A10 SMCs were serum-starved for 48 hours. Che-
motaxis with and without PDGF-BB (5 ng/mL) was evaluated (n

 3; *P 	 0.05, compared to AdNull control or PDGF-BB).inhibition of PKC caused SMCs to become resistant toapoptotic stimuli.18 Conversely, overexpression of the
wild-type PKC induced a small increase (about 25%) in
cell death in the absence of exogenous stimuli, such as
PMA.18 Thus, both PKC-mediated cell apoptosis and
growth inhibition could contribute to the reduction in cell
number and DNA synthesis of PKC-overexpressing cells.
The importance of PKC to normal cell migration is
only recently receiving increased attention, despite the
PKC isotype having been shown 10 years ago to be
intimately related to the cytoskeleton.2 In previous experi-
ments, we found that phorbol ester–induced general acti-
vation of PKC in human saphenous vein SMCs resulted in
a significant reduction in PDGF-stimulated chemotaxis.
PKC is one of the four PKC isotypes subsequently identi-
fied as potential mediators of this effect.1
In this study, we showed that overexpression of exog-
enous PKC in vascular SMCs led to inhibition of PDGF-
stimulated chemotaxis. This result, along with a recent
report by Grahm et al19 in which prolonged PKC activa-
tion inhibits endothelial chemotaxis, suggests that the role
of PKC in cell migration is inhibitory.
The decreased migration and proliferation seen in
SMCs from PKC-deficient mice, however, suggests that a
brief increase in PKC activation may be necessary for both
processes. Similarly, Li et al20 reported diminished migra-
tion of similar SMCs when stimulated with mechanical
stress. This dual role of PKC emphasizes the complexity of
SMC chemotaxis and proliferation.
To elucidate how PKC overexpression affects prolif-
eration and migration, two distinct cellular processes, we
turned attention to the MAPK ERK1/2 pathway, an estab-
lished mediator of both proliferation and migration in
vascular SMCs. We showed in both A10 and adult
RASMCs that ERK1/2 activation by PDGF-BB is greatly
impaired by exogenous PKC expression. Given the critical
role of ERK1/2 in proliferation and migration, it is plausi-
ble that prolonged activation of PKC inhibits SMC pro-
liferation and migration by suppressing the ERK1/2 cas-
cade. PKC is a recognized stimulant of ERK1/2;
specifically, several isotypes of PKC (, 1, and ε) have
been found to both activate ERK1/2 as well as stimulate
proliferation in vascular SMCs.21-23 Thus, our findings
with PKC are novel and suggest an additional role of
PKC that is divergent from that of the other PKC isotypes.
We also previously reported PKC is physically associ-
ated with another MAPK, p38, in SMCs.18 Protein se-
quence analysis, however, failed to disclose any consensus
motifs within ERK1/2 that could serve as phosphorylation
sites for PKC. This suggests that PKC may affect
ERK1/2 indirectly.
This study illuminates one of several possible signaling
pathways through which PKC induces growth arrest. In-
deed, it is likely that PKC halts cell growth through
multiple routes. We have previously shown that PKC
upregulates p53 in vascular SMCs,18 suggesting another
mechanism by which PKC could regulate the cell cycle
and inhibit proliferation. This course has been studied in
human breast cancer24 and lung adenocarcinoma25 cells.
JOURNAL OF VASCULAR SURGERY
Volume 45, Number 1 Liu et al 167These studies show that PKC induces p21, a downstream
target of p53, resulting in G1 phase arrest; however, the
upregulation of p21 occurs independently of p53 in many
cell types.26,27 In addition, conflicting reports exist about
PKC’s ability to upregulate p21 in vascular SMCs.28,29
Similar to its dual effects on cell proliferation and
migration, PKCmay be both inhibitory and stimulatory to
the ERK1/2 pathway. Ginnan and Singer30 recently
showed, also in SMCS, that inhibition of PKC via a
dominant negative mutant blocked activation of ERK1/2
in response to PDGF-BB, suggesting that PKC is neces-
sary for the activation of this MAP kinase.30 Whether the
diminished ERK1/2 activity underlies the reduction in
proliferation and migration that we observed in PKC null
cells remains to be investigated.
Although our current knowledge of PKC does not
provide us with an explanation of how a single protein
kinase can be both stimulatory and inhibitory to similar
cellular functions, PKC would not be alone in possessing
this property. The Rho family of regulatory GTPases also
exhibit dual effects on SMC behavior. Activation of the
Rho/Rho kinase pathway is necessary for stimulated pro-
liferation and migration.31 If that activation is prolonged,
however, migration is inhibited while proliferation remains
increased.32 Interestingly, evidence exists to support a re-
lationship between PKC and Rho.20,33
Our in vivo findings suggest that diminished PKCmay
in part contribute to the accumulation of SMCs in the
neointima after arterial injury. Indeed, PKC-null mice,
despite their normal and fertile appearance, showed in-
creased B-cell proliferation and autoimmunity and exacer-
bated lesion formation in a vein-graft vascular injury
model.11,34 In the vein graft study, intimal hyperplasia was
found to be 50% greater in grafts derived from PKC-null
mice than in wild-type grafts. At 8 weeks after grafting,
there was about an 80% reduction in apoptosis within the
PKC-null graft; surprisingly, no significant change in pro-
liferation was observed. Whether PKC deletion affects
SMC proliferation after vascular injury remains unclear, as
proliferation peaks at an earlier time point than those
evaluated.
CONCLUSION
We have demonstrated, through both genetic and mo-
lecular manipulation, that prolonged PKC can be both
inhibitory and stimulatory in its regulation of proliferation
and migration in vascular SMCs. Furthermore, activation
of the MAP kinase ERK1/2 is downregulated by overex-
pression of PKC, which could, at least in part, mediate
PKC’s inhibitory effect. Since it is known that PKC is
activated by mitogenic stimuli such as PDGF-BB, PKC
activation could serve as a negative feedback mechanism to
keep SMC proliferation and migration under control. A
diminution of this feedback pathway, such as that observed
in injured arteries, could contribute to undesired SMC
proliferation and migration, which in turn leads to the
formation of intimal hyperplasia.We thank Chunjie Wang and Sophia Chu for their
technical assistance. We also thank Dr N. Heckatte at The
Gene Therapy Core Facility, Weill Cornell Medical Col-
lege, for assistance with adenovirus preparation.
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